Even some psychiatrists have acknowledged that the last fifty years of their medicating those diagnosed with schizophrenia – the umbrella term for most mental illnesses – has not been
particularly successful. Big Pharma is on board with that assessment and is now investing millions in research into “breakthrough therapy” psychedelic-based medication to treat any number of mental disorders.

     LSD, psilocybin and MDMA are all being tested in preparation for the first FDA approved clinical trials for these hallucinogens to be used to treat depression and anxiety as well as other mental “disorders.”
Never mind that all three drugs have been classified as illegal Schedule 1 drugs that have a “high potential for abuse” and are without any “currently accepted medical use in treatment”.

     Even the United States Drug Enforcement Administration has reported that the use of LSD in psychotherapy largely has been debunked, and “drug studies have confirmed that the powerful hallucinogenic effects of this drug can produce profound adverse reactions, such as acute panic reactions, psychotic crises, and “flashbacks”, especially in users ill-equipped to deal with such trauma.”

     In the 1950s psychiatrists used LSD research to try to replicate the effects of mental illness, and their infamous MKUltra experiments used LSD covertly on often unsuspecting subjects to develop workable mind control techniques.

     So why are so many dollars now pouring into what should be questionable psychedelic research?

     Because the psychedelic therapeutics market has been valued at $2 billion in 2023 and it is expected to grow to $7 billion by 2031.

     Nonprofits like the Multidisciplinary Association for Psychedelic Studies (MAPS) — now valued at $97 million in assets, all through donations — are cashing in on this psychedelics research gold rush. They have even donated over $20 million themselves to other organizations studying the use of psychedelics for therapeutic applications.

     Just who are these new gold rush carpetbaggers?

     MAPS therapists were videoed in 2022 spooning and pinning down a Phase 2 clinical trial participant in one study for the use of MDMA for PTSD therapy, as reported by New York Magazine. After that session one of the therapists sexually coerced the patient and the patient moved in with the therapists for the next two years.

     MAPS lists Vicky Dulai as one of its three member Board of Directors. She “advises philanthropists and foundations about emerging opportunities in psychedelic research, treatment, and therapist training.” Vicky is their (very successful) fundraiser.

     In May, 2021 Vicky was alleged in a civil lawsuit of exploiting multi-millionaire venture capitalist George Sarlo, then in his eighties, to extract more than $4 million from him while acting as his “psychedelic therapist” and feeding him ayahuasca, MDMA, and Ketamine.

     The two of them had started a romantic relationship before he had had his first psychedelic  experience.

     Sarlo gifted her $1.4 million for a house that she, her husband and children, had moved into. He “loaned” $190,000 to her husband for a business investment and he gave her a $65,000 Porsche.

     Vicky used $30,000 of Sarlo’s philanthropic funds for private schooling for her children, received a $5150 monthly salary as director of his charitable foundation, and in just the first quarter of 2021 withdreaw more than $300,000 from Sarlo’s personal checking account to fly with her family and Sarlo to Hawaii on a private jet that itself cost $75,000.

     The civil case against Vicky was settled out of court and no criminal charges were ever filed. She and Sarlo often participated together in psychedelic fundraising and networking events, and after Sarlo made a $1 million donation to MAPS, Vicky was given her seat on the board of directors.

     That’s who these carpetbaggers are. 

     Back in 1998, a United Nations report estimated that the illegal synthetic drug market at that time, which included psychedelics, was $60 million.

     Today’s unscrupulous opportunists like Vicky Dalai are doing their best to ensure this new, legal psychedelic drug market is not far behind.